Brain Receptors in Sympathetic Nervous System Regulation
Information source: National Institutes of Health Clinical Center (CC)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Yohimbine (Drug)
Sponsored by: National Institute of Mental Health (NIMH)
The purpose of this study is to investigate the role of brain receptors called
alpha2-adrenoreceptors in regulating the sympathetic nervous system, which maintains the
supply of blood and fuel to the body's organs in times of stress, fear, anger, or exercise.
Alpha(2)-adrenergic receptors (alpha(2)-AR) play a role in a variety of physiological
functions. There are three subtypes of alpha(2)-ARs, and their differences are unknown. This
study will examine the functional roles of these three subtypes by comparing the behavioral,
biochemical, psychophysiological, and autonomic function effects of the alpha(2)-AR drugs
clonidine and yohimbine.
Participants in this study will undergo a physical examination, electrocardiogram (ECG), and
blood, urine, and saliva tests. Women will have hormone tests to determine the time of their
last period and the time of their next ovulation. Participants will undergo
neuropsychological testing and other procedures.
Official title: Alpha(2)-Adrenoreceptor (AR) Subtype Polymorphisms and Physiological Responses to Alpha(2)-AR Agonist and Antagonist Drugs
Study design: N/A
Alpha(2)-adrenergic receptors (alpha(2)-AR) are cell surface receptors for catecholamines
that bind to the G(i)/G(0) family of G proteins. Alpha(2)-ARs are widely distributed in the
central and peripheral nervous system, and are known to play an important role in the
regulation of catecholamine release. This mechanism and the broad distribution of these
receptors explain their role in a wide variety of physiological functions. Alpha(2)-AR
mediate central hypotensive, sedative, anesthetic, and analgesic responses to alpha(2)-AR
agonists. However, cardiovascular and other responses to the alpha(2)-AR agonists are
subject to interindividual variation in the human population. Such variability may be
explained by genetic variation in the structure of the receptors themselves, the cognate G
proteins, the transductional effectors, or the downstream intracellular targets. Molecular
and pharmacological research has defined three alpha(2)-ARs subtypes designated alpha(2)(A),
alpha(2)(B), and alpha(2)(C). All three alpha(2)-AR subtypes are involved in the regulation
of blood pressure, and these receptors also modulate sedation, analgesia, regulation of
insulin release, renal function, cognition and behavior. Biochemical research has identified
three human genes that uniquely encode these alpha(2)-ARs. Recently, in preclinical studies
polymorphisms of all three alpha(2)-AR subtypes have been described. The three polymorphisms
are each relatively abundant, and two appear to be functional in vitro. However, in humans
the in vivo physiological effect of these polymorphisms is unknown.
This study will elucidate the potential functional role of the three alpha(2)-AR subtypes in
humans by comparing the behavioral, biochemical, psychophysiological, and autonomic function
effects of the well-established alpha(2)-AR agonists and antagonists, clonidine and
yohimbine, respectively, in individuals selected for particular alpha(2)-AR genotypes. Based
on preclinical studies the following hypotheses will be tested: 1) subjects homozygous or
heterozygous for the alpha(2)(A)-AR Asn251Lys substitution will show a potentiation of
clonidine-induced effects, relative to subjects who have the Asn251/Asn251 genotype, and a
reduction of yohimbine-induced effects, 2) subjects homozygous or heterozygous for a
alpha(2)(B)-AR three glutamic acid deletion (residues 301-303) will show reduced effects of
the alpha(2)-AR agonist clonidine and possibly a potentiation of effects of yohimbine, and 3)
we will evaluate whether altered responses in either direction occur in subjects homozygous
and heterozygous for an in-frame deletion of a alpha(2)(C)-AR homologous repeat occurring at
codons 322-325 relative to subjects without this deletion allele.
Minimum age: N/A.
Maximum age: N/A.
Healthy subjects with a negative first-degree family history of psychiatric disorders as
determined by the Family Interview of Genetic Studies are eligible.
Subjects must be willing to participate in a challenge study.
Subjects must be in good physical health.
Subjects must have the absence of any Axis I and Axis II DSM-IV diagnosis.
Subjects will be excluded if they have evidence for an axis I psychiatric disorder or the
presence of an axis II personality disorder.
Smokers are ineligible to participate.
Subjects with recent life stressors (3 months) or chronic life stressors (1 year) will be
Subjects must be between the ages of 18 and 50.
Subjects must meet criteria for one of 6 genotypically defined subgroups.
Subjects must not have taken antidepressant or other medications likely to alter monoamine
neurochemistry or cerebrovascular and cardiovascular function for at least 6 months prior
to the challenge studies.
Subjects will be excluded if they have medical or neurological illnesses likely to affect
physiology or anatomy, i. e. hypertension, cardiovascular disorders.
Subjects must not have a history of drug (including BZDs) or alcohol abuse within 1 year or
a lifetime history of alcohol or drug dependence.
Subjects with current or previous regular use (greater than 4 weeks) of BZDs and excessive
use of alcohol (greater than 8 ounces/week for men and greater than 6 ounces/week for
women) in the past or present are ineligible to participate.
Women who are currently pregnant or breastfeeding are not eligible.
Subjects who cannot hear a 40 dB(HL) pure tone in the 1000- to 4000 Hz span (Welsh Allen
audioscope) will be excluded from studies.
Locations and Contacts
National Institute of Mental Health (NIMH), Bethesda, Maryland 20892, United States
Eisenhofer G, Esler MD, Meredith IT, Dart A, Cannon RO 3rd, Quyyumi AA, Lambert G, Chin J, Jennings GL, Goldstein DS. Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine. Circulation. 1992 May;85(5):1775-85.
O'Dowd BF, Lefkowitz RJ, Caron MG. Structure of the adrenergic and related receptors. Annu Rev Neurosci. 1989;12:67-83. Review.
Venter JC, Fraser CM, Kerlavage AR, Buck MA. Molecular biology of adrenergic and muscarinic cholinergic receptors. A perspective. Biochem Pharmacol. 1989 Apr 15;38(8):1197-208. Review. No abstract available.
Starting date: January 2002
Ending date: December 2004
Last updated: March 3, 2008